Wolstan & Goldberg Eye Associates Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2014
NCT02163824
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Wolstan & Goldberg Eye Associates